Evidence map›Paper›PMID 28572622›Full record

ArticleScientific reports2017

Probing the action of a novel anti-leukaemic drug therapy at the single cell level using modern vibrational spectroscopy techniques.

Joanna L Denbigh, David Perez-Guaita, Robbin R Vernooij, Mark J Tobin, Keith R Bambery, Yun Xu, Andrew D Southam, Farhat L Khanim, Mark T Drayson, Nicholas P Lockyer and 2 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
4.0field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 32 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Infrared Spectroscopy: A New Frontier in Hematological Disease Diagnosis.International journal of molecular sciences · 2023
    Review
  6. Analytical Techniques for Single-Cell Biochemical Assays of Lipids.Annual review of biomedical engineering · 2023
    Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 2 countries.

Joanna L DenbighManchester Institute of Biotechnology and School of Chemistry, University of Manchester, Manchester, M1 7DN, United Kingdom.
David Perez-GuaitaCentre for Biospectroscopy and School of Chemistry, Monash University, Clayton, Victoria, 3800, Australia.ORCID 0000-0002-2640-2927
Robbin R VernooijCentre for Biospectroscopy and School of Chemistry, Monash University, Clayton, Victoria, 3800, Australia.
Mark J TobinAustralian Synchrotron, 800 Blackburn Road, Clayton, Victoria, 3168, Australia.ORCID 0000-0003-1862-0649
Keith R BamberyAustralian Synchrotron, 800 Blackburn Road, Clayton, Victoria, 3168, Australia.ORCID 0000-0002-8489-1749
Yun XuManchester Institute of Biotechnology and School of Chemistry, University of Manchester, Manchester, M1 7DN, United Kingdom.
Andrew D SouthamSchool of Biosciences, University of Birmingham, Birmingham, B15 2TT, United Kingdom.
Farhat L KhanimSchool of Biosciences, University of Birmingham, Birmingham, B15 2TT, United Kingdom.
Mark T DraysonInstitute of Immunology and Immunotherapy, University of Birmingham, Birmingham, B15 2TT, United Kingdom.
Nicholas P LockyerManchester Institute of Biotechnology and School of Chemistry, University of Manchester, Manchester, M1 7DN, United Kingdom.
Royston GoodacreManchester Institute of Biotechnology and School of Chemistry, University of Manchester, Manchester, M1 7DN, United Kingdom.ORCID 0000-0003-2230-645X
Bayden R WoodCentre for Biospectroscopy and School of Chemistry, Monash University, Clayton, Victoria, 3800, Australia. Bayden.Wood@monash.edu.
University of Manchester · GBMonash University · AUUniversity of Birmingham · GBAustralian Synchrotron · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Acute myeloid leukaemia (AML) is a life threatening cancer for which there is an urgent clinical need for novel therapeutic approaches. A redeployed drug combination of bezafibrate and medroxyprogesterone acetate (BaP) has shown anti-leukaemic activity in vitro and in vivo. Elucidation of the BaP mechanism of action is required in order to understand how to maximise the clinical benefit. Attenuated total reflectance Fourier transform infrared (ATR-FTIR) spectroscopy, Synchrotron radiation FTIR (S-FTIR) and Raman microspectroscopy are powerful complementary techniques which were employed to probe the biochemical composition of two AML cell lines in the presence and absence of BaP. Analysis was performed on single living cells along with dehydrated and fixed cells to provide a large and detailed data set. A consideration of the main spectral differences in conjunction with multivariate statistical analysis reveals a significant change to the cellular lipid composition with drug treatment; furthermore, this response is not caused by cell apoptosis. No change to the DNA of either cell line was observed suggesting this combination therapy primarily targets lipid biosynthesis or effects bioactive lipids that activate specific signalling pathways.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsBezafibrateHL-60 CellsHumansLeukemia, Myeloid, AcuteMedroxyprogesteroneSpectroscopy, Fourier Transform InfraredSpectrum Analysis, RamanSynchrotronsBezafibrateMedroxyprogesterone

Identifiers

PMID28572622
PMCPMC5453947
OpenAlexW2608728628

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.